Charcot–Marie–Tooth disease (CMT) is the most common form of hereditary neuropathy. With the advent of new molecular techniques like NGS, the clinical and genetic spectrum of CMT has been greatly expanded .Our aim is to review the recent research advances in CMT in the last five years (2012-2016), including an update on classification and genetic spectrum, additions to the algorithm for CMT diagnosis and the developments of new animal models and biomarkers. We will also discuss the progress in potential treatments for CMT. Though there is still no effective therapy to date, a number of large-scales new therapeutic trials such as PXT3003 may give hopes for curative therapies.
No takes yet. Share an insight, caveat, or question.
A 2018 study studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: